[KongchangAI]
Unverified88% confidenceFactTime unknown

Menveo获批可用于2月龄及以上人群,相比某些竞品(如Menactra需9月龄起)在婴幼儿低龄接种上有适用优势

1
Sources
88%
Confidence
Long-term
Relevance
-
First Seen

Sources

Related Entities

Related Claims

Cite This Claim

Stable URI
https://kongchang.com/claim/643003
API
curl https://kongchang.com/api/v1/knowledge/claims/643003
MCP
get_claim(id=643003)